Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.
d'Oiron R, Volot F, Reynaud J, Peerlinck K, Goudemand J, Guérois C, Rothschild C, Chambost H, Borel-Derlon A, Roussel-Robert V, Marquès-Verdier A, Lienhart A, Berthier AM, Moreau P, Lambert T; MHAI Study Group. d'Oiron R, et al. Among authors: chambost h. Semin Hematol. 2006 Jan;43(1 Suppl 1):S3-9. doi: 10.1053/j.seminhematol.2005.11.002. Semin Hematol. 2006. PMID: 16427382
Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.
Calvez T, Chambost H, Claeyssens-Donadel S, d'Oiron R, Goulet V, Guillet B, Héritier V, Milien V, Rothschild C, Roussel-Robert V, Vinciguerra C, Goudemand J; FranceCoag Network. Calvez T, et al. Among authors: chambost h. Blood. 2014 Nov 27;124(23):3398-408. doi: 10.1182/blood-2014-07-586347. Epub 2014 Sep 24. Blood. 2014. PMID: 25253771 Free article.
Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.
Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ. Liesner RJ, et al. Among authors: chambost h. Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16. Haemophilia. 2018. PMID: 28815880 Clinical Trial.
Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J; for FranceCoag Collaborators. Calvez T, et al. Among authors: chambost h. Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12. Haematologica. 2018. PMID: 29025913 Free PMC article.
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study.
Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P. Resseguier N, et al. Among authors: chambost h. BMJ Open. 2018 Jul 25;8(7):e022409. doi: 10.1136/bmjopen-2018-022409. BMJ Open. 2018. PMID: 30049701 Free PMC article.
171 results